# NiKang Therapeutics

Source: https://onco.cc/companies/nikang-therapeutics/  
OnCo record `nikang-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A US company making pills that block or break down cancer-driving proteins. Its drugs are in early trials for kidney cancer, liver cancer, hormone-receptor-positive breast cancer and other solid tumours.

## Summary

NiKang Therapeutics develops small molecules for oncology targets, using structure-based drug design. NKT2152 is an oral HIF2-alpha inhibitor tested in a Phase 1/2 study in advanced clear cell renal cell carcinoma (NCT05119335, now terminated) and, in collaboration with Roche, with atezolizumab and bevacizumab in first-line hepatocellular carcinoma in the MORPHEUS-Liver platform study. NKT3964 is an oral CDK2 PROTAC degrader in a Phase 1 study in advanced solid tumours (NCT06586957), now enrolling CCNE1-amplified endometrial cancer, and NKT5097 is an oral CDK2/CDK4 dual degrader in a Phase 1 study alone and with endocrine therapy in HR-positive, HER2-negative breast cancer (NCT07029399). The company's timeline states it was incorporated in July 2017 and raised a $10 million Series A (December 2017), a $50 million Series B (September 2020) and a $200 million Series C (May 2021), and lists collaborations with Erasca (SHP2), Pfizer, Hansoh and Roche (HIF2).

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: NiKang Therapeutics, Inc.; Nikang Therapeutics
- HQ: Wilmington, DE
- Type: biotech
- Website: https://www.nikangtx.com/

## Notes

- The company's pipeline page cites MORPHEUS-Liver as NCT04524781, which the ClinicalTrials.gov API does not find; the MORPHEUS-Liver study that includes NKT2152 is NCT04524871 (sponsor Hoffmann-La Roche, in OnCo as nct04524871). It is not linked here because NiKang is not the sponsor.
- NCT05119335 and NCT05935748 (NKT2152, both terminated), NCT06586957 and NCT07029399 were confirmed through the ClinicalTrials.gov v2 API; none is a trial record in OnCo yet.
- CDK4 is not linked separately because OnCo holds only a combined CDK4/6 target.

## Sources

- Official website: https://www.nikangtx.com/
- Science and pipeline page: https://www.nikangtx.com/science-and-pipeline/
- About us and company timeline: https://www.nikangtx.com/about-us/
- RA Capital portfolio entry: https://www.racap.com/portfolio/nikang-therapeutics

## Connected records

- cancers: [Clear cell renal cell carcinoma](https://onco.cc/cancers/clear-cell-rcc/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [CDK2](https://onco.cc/targets/cdk2/), [HIF-2α](https://onco.cc/targets/hif2a/)
- drugs: [NKT2152](https://onco.cc/drugs/nkt2152/), [NKT3964](https://onco.cc/drugs/nkt3964/), [NKT5097](https://onco.cc/drugs/nkt5097/)
- companies: [RA Capital Management](https://onco.cc/companies/ra-capital/)
- trials: [A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma](https://onco.cc/trials/nct05119335/), [A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06586957/), [A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct07029399/), [Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)](https://onco.cc/trials/nct05935748/)

---
JSON: https://onco.cc/api/v1/entities/nikang-therapeutics.json